Hypothyroidism in patients with multiple myeloma (MM) receiving thalidomide.

被引：0
|
作者：
Badros, A
Zangari, M
Bodenner, D
Siegel, E
Spoon, D
Toor, A
Desikan, R
Arnold, E
Anaissie, E
Zeldis, J
Tricot, G
Barlogie, B
机构：
[1] Univ Arkansas Med Sci, Myeloma & Transplantat Res Ctr, Little Rock, AR 72205 USA
[2] Univ Arkansas Med Sci, Dept Endocrinol, Little Rock, AR 72205 USA
[3] Celgene Corp, Warren, NJ USA
来源：
BLOOD | 2000年 / 96卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4973
引用
收藏
页码：285B / 285B
页数：1
相关论文
共 50 条
  • [1] Angiogenesis and angiogenic cytokines in patients receiving thalidomide for multiple myeloma (MM).
    Thompson, MA
    Witzig, TE
    Timm, MM
    Haug, J
    Kumar, S
    Fonseca, R
    Greipp, PR
    Rajkumar, SV
    BLOOD, 2002, 100 (11) : 811A - 811A
  • [2] Erythropoietin therapy and venous thromboembolic events in patients with multiple myeloma receiving chemotherapy with or without thalidomide.
    Zangari, Maurizio
    Cavallo, Federica
    Prasad, Keshava
    Fink, Louis
    Coon, Sharon
    Barlogie, Bart
    Tricot, Guido
    BLOOD, 2006, 108 (11) : 1020A - 1020A
  • [3] Renal failure (RF) in multiple myeloma (MM) - Possible association with pamidronate and thalidomide.
    Yudis, M
    Sirota, RA
    Stein, HD
    Snipes, ER
    Gronich, JH
    Ghantous, VE
    Collins, DM
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2002, 13 : 733A - 734A
  • [4] Hypothyroidism in patients with multiple myeloma following treatment with thalidomide
    Badros, AZ
    Siegel, E
    Bodenner, D
    Zangari, M
    Zeldis, J
    Barlogie, B
    Tricot, G
    AMERICAN JOURNAL OF MEDICINE, 2002, 112 (05): : 412 - 413
  • [5] Increased marrow CD57+cytotoxic T cells is a powerful prognostic marker for survival in patients with relapsed multiple myeloma (MM) receiving thalidomide.
    Mileshkin, LR
    Gambell, P
    Beshay, V
    Hayakawa, Y
    Smyth, M
    Trivett, M
    Simmons, PJ
    Milner, A
    Zeldis, JB
    Prince, M
    BLOOD, 2005, 106 (11) : 973A - 973A
  • [6] Acute myeloid leukemia in patient with multiple myeloma treated with thalidomide.
    Novoselac, AV
    Reddy, S
    Ohsumi, F
    Sherman, RE
    Samaha, S
    BLOOD, 2003, 102 (11) : 382B - 382B
  • [7] A systematic review of the incidence of venous thromboembolism (VTE) and effectiveness of prophylaxis in patients with multiple myeloma (MM) receiving thalidomide
    Wu, C. M.
    Lee, A. Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [8] NK cell repertoire in myeloma and the impact of thalidomide.
    El-Sherbiny, YM
    Davies, FE
    Cook, G
    Johnson, RJ
    Cullen, MJ
    Sah, A
    Rawstron, AC
    Richards, SJ
    Morgan, GJ
    BLOOD, 2003, 102 (11) : 443A - 443A
  • [9] Long term survival and complete remission of chemotherapy refractory multiple myeloma with thalidomide.
    Helgason, HH
    Smit, WM
    de Groot, MR
    Schenkeveld, CEI
    Neef, C
    Schaafsma, MR
    BLOOD, 2002, 100 (11) : 387B - 387B
  • [10] Thromboembolism in multiple myeloma patients receiving thalidomide combination chemotherapy.
    Wrigh, A.
    Elkins, S.
    Files, J.
    Bigelow, C.
    Herrin, V.
    Sample, M.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2007, 55 (01) : S302 - S302
12345